Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

Abstract Background The increasing number of treatments that are now available to manage patients with multiple sclerosis (MS) highlights the need to develop biomarkers that can be used within the framework of individualized medicine. Fingolimod is a disease-modifying treatment that belongs to the s...

Full description

Bibliographic Details
Main Authors: Celia Camacho-Toledano, Isabel Machín-Díaz, Leticia Calahorra, María Cabañas-Cotillas, David Otaegui, Tamara Castillo-Triviño, Luisa María Villar, Lucienne Costa-Frossard, Manuel Comabella, Luciana Midaglia, José Manuel García-Domínguez, Jennifer García-Arocha, María Cristina Ortega, Diego Clemente
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Journal of Neuroinflammation
Subjects:
EAE
MDSCs
S1PR
Responder and non-responder
Personalized medicine
Online Access:https://doi.org/10.1186/s12974-022-02635-3

Internet

https://doi.org/10.1186/s12974-022-02635-3

Similar Items